Financial Performance - The company reported a basic earnings per share of -0.4737 yuan for 2024, a significant decrease of 1950.39% compared to 0.0256 yuan in 2023 [1] - The total revenue for 2024 was 4.73 billion yuan, down 36.08% from 7.4 billion yuan in 2023 [1] - The net profit for 2024 was -2.16 billion yuan, a drastic decline from a profit of 0.12 billion yuan in 2023, representing a 1900% decrease [1] - The return on equity for 2024 was -17.46%, a sharp drop from 0.87% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 14,688.49 million shares, accounting for 33.33% of the circulating shares, with a decrease of 493,500 shares compared to the previous period [2] - Hainan Hongshi Investment Co., Ltd. remains the largest shareholder with 12,403.87 million shares, representing 28.15% of the total share capital, unchanged from the previous report [3] - Zhu Jun increased his holdings by 70,000 shares, now holding 500,000 shares, which is 1.13% of the total [3] - New entrants to the top shareholders include Han Wenjing with 392.83 million shares (0.89%) and Xu Shanglong with 205.98 million shares (0.47%) [3] - Notable exits from the top ten shareholders include Tang Youde, UBS AG, and Duan Wenjing [3]
康芝药业:2024年报净利润-2.16亿 同比下降1900%